Introduction
HIV type 1 (HIV-1) infection is a disease of public health importance with a significant burden on the quality of life of the affected individuals and national economy [1] [2] [3] [4] [5] . In 2009, an estimated 370 000 infants contracted HIV infection during the perinatal and breastfeeding period [6, 7] . AIDS-related deaths are decreasing globally mainly due to the increased availability of HAART as well as care and support for people living with HIV/AIDS [8, 9] . The risk of vertical transmission of HIV between mother and child varies significantly between less than 1 and 25% [10] [11] [12] [13] . The wide transmission variability may be due to maternal viral load, antiretroviral therapy (ART) administration to the mothers, presence of coexisting infections such as tuberculosis, hepatitis B virus, hepatitis C virus, gestational age at which the foetus is exposed to the virus and the evolution of the virus under the maternal immune pressure [14, 15] . The prevalence of paediatric HIV infection in France was less than 1% [16] and in South Africa was 7.5% [17] ; however, a prevalence of 10% has been reported for paediatric HIV infection in Nigeria [18] .
Hearing loss is a significant global health problem [19, 20] with a significant impact on speech and language development, emotional status, social life, education as well as ultimate employability of the child in future, especially in low and middle-income countries such as Nigeria [19] [20] [21] [22] [23] [24] [25] . The cause of hearing loss in the newborn includes mitochondrial abnormalities, genetic or congenital malformations, neurologic disorders or damage secondary to congenital infections such as cytomegalovirus (CMV), toxoplasmosis and rubella [26] [27] [28] [29] [30] . Others are intrauterine exposure to ototoxic medications [26] [27] [28] [29] [30] and HIV infection [19, [31] [32] [33] .
In most resource-limited countries, there is no universal hearing screening for newborns and hearing loss is infrequently detected at an age when language acquisition would have passed. In Nigeria, the only newborn hearing screening showed 6.5% hearing impairment [24] , while 2.8-14.5% hearing impairment was found in Nigerian infants and/or elementary school children [21, 23, 25] . Although the coexistence of HIV/AIDS infection and hearing loss may significantly impact the child's quality of life, studies have also shown that some antiretroviral medications are associated with tinnitus and hearing loss [34] . There are also reports of hearing impairment in adults and children receiving antiretroviral medications [35, 36] . In particular, nucleoside reverse transcriptase inhibitor class of ART is associated with hearing loss in perinatally HIV-infected children because of its mitochondrial dysfunctional effect [37, 38] . There is however limited knowledge on the effect of HIV and antiretroviral medications on the integrity of hearing of the exposed newborns in sub-Saharan Africa where the disease is prevalent. Early identification of hearing impairment, by any electrophysiological audiometric tests, with appropriate intervention or rehabilitation will reduce the period of auditory deprivation leading to an improved speech and language development. Therefore, this study determined the prevalence of sensorineural hearing loss (SNHL) among HIV-1 exposed newborns as well as the association between their hearing threshold and maternal RNA viral load, CD4 þ cell counts and HAART administration.
Materials and methods

Study design
This was a cohort audiometric study of newborns in Ibadan, Nigeria, involving consecutive HIV-1 exposed and HIV-unexposed newborns studied between October 2012 and April 2013. The study was approved by the Joint University of Ibadan/ University College Hospital, Ibadan, Nigeria Ethical Review Committee and informed consent was obtained from each parent.
Sampling method
All the consecutive newborns of mothers during the study period at the two study locations were recruited. Inclusion criterion was a live healthy newborn aged 1 month or less. The HIV-exposed were newborns of HIV-1 infected mothers, whereas the HIV-unexposed were newborns of HIV-uninfected mothers. HIV-exposed newborns were recruited from the postnatal HIV clinics at the University College Hospital, Ibadan and Adeoyo Maternity Hospital, Ibadan, Nigeria, supported by the President's Emergency Plan For AIDS Relief (PEPFAR) and AIDS Prevention Initiative Nigeria (APIN), whereas the HIV-unexposed newborns were recruited from the immunization clinics of the same hospitals. HIV screening and Venereal Disease Research Laboratory (VDRL) tests are routine for mothers at the antenatal clinics of these hospitals.
Data collection procedures and interventions
Structured questionnaires A structured questionnaire detailing family sociodemographic data and risk factors associated with hearing loss in the newborns was administered to each mother. Clinic records documenting types of HAART, time of commencement of HAART in relation to the index pregnancy and the duration of therapy by mothers were retrieved.
Virology and Immunology
Blood sample was collected from all the HIV-exposed newborns for HIV-DNA PCR, CD4 þ cell count and CD4 þ % determination at the Virology Laboratory of University College Hospital, Ibadan. The mothers' HIV status, VDRL test result and the last CD4 þ cell count (cells/ml) and RNA viral load (copies/ml) determined during the pregnancy of the index newborns were retrieved from their antenatal records kept at the PEPFAR/APIN clinic records unit. The protocol of the study centres included determination of the CD4 þ cell count and plasma viral loads of HIV-infected mothers at every 3 months in pregnancy. CD4 þ cell count and CD4% (percentage of lymphocytes that are CD4 þ ) were determined using the Partec (Munster, Germany) CD4 þ easy count and CD4 þ % easy count kits, respectively. Both assays were based on the principle of no lyse, no wash. HIV-DNA detection (for early infant HIV diagnosis) and HIV-RNA quantification were done using the Roche HIV-DNA and HIV-1 RNA Amplicor version 1.5, respectively. The lower and upper detection limits of the HIV viral load assay are 400 and 750 000 copies/ml of plasma, respectively.
Auditory brainstem response test
The Auditory Brainstem Response (ABR) audiometry was performed on all the participants in the Audiology Booth of the Audiology Unit of the Department of Otorhinolaryngology, University College Hospital (UCH), Ibadan. Hearing thresholds after sedation with chlorhydrate (70 mg/kg) were estimated with automatic ABR-test system [MAICO MB 11 Classic (MAICO Diagnostic GmbH, Salzufer, Berlin, Germany]. Disposable electrode sticky pads were attached to the top of the forehead (vertex), the right and left mastoid regions and appropriate sized ear tips were inserted into the ear canals. The ABR waveforms were generated after an automated click stimulus was presented mono-aurally to each tested ear. Both ears were tested. The hearing screening was electronically reported as pass (no impairment of hearing) if there was response at a test level of 35 dB or refer (presence of hearing impairment) if there was no response at 35 dB. To obtain the participants' estimated hearing threshold levels in this study, both standard and Time Step Stimulus ABR tests were performed. Time step stimulus uses 'packets' of six clicks following each other very rapidly in which the intensity increases in 10 dB increments for each click in the packet. The entire click packets were presented in 25 ms. The maximum output of the click stimulus was 70 dB. ABR threshold was defined as the lowest stimulus level at which wave V was still present and reproducible and was determined in 10-dB steps. In this study, hearing impairment was defined as hearing threshold more than 20 dBHL at frequencies of 1-8 KHz.
Data analysis
The demographic variables of age, sex, family history of hearing loss, use of ototoxic medication in pregnancy and the duration of use, birth asphyxia, body rashes in mothers during pregnancy, cleft lip/palate for the HIV-exposed newborn were compared with the data from HIVunexposed newborns. The statistical analysis was performed using Statistical Package for Social Sciences (SPSS Inc., Chicago, Illinois, USA) Version 17. Proportions were compared using chi-square with Yates' correction or Fisher's exact tests. Normally distributed, continuous variables were compared by Student's t-test for independent group. The association between hearing threshold of the HIV-exposed newborns and their mother's RNA viral load and CD4 þ cell count level as well as HAART administration was tested with Pearson chi-square. Level of significance was determined at a P value less than 0.05, two-tailed level at 95% confidence interval (CI) and correlation coefficient (r). We calculated a sample size of 98 using estimated prevalence of hearing loss of 4.1% in HIV-exposed newborns and 1.2% in HIV-unexposed newborns; putting into consideration 20% attrition rate, the minimum sample size was further increased to 120 in each category.
Results
Socio-demographic and clinical characteristics
One hundred and twenty-six HIV-exposed newborns comprising 72 (57.1%) boys and 54 (42.9%) girls and 121 HIV-unexposed newborns comprising 69 (57%) boys and 52 (43%) girls were studied. The mean age of 2.87 AE 1.05 in HIV-exposed newborn and 2.84 AE 1.04 weeks in HIVunexposed newborns was similar (P ¼ 0.868). Risk factors of SNHL between the two groups were similar (Table 1 ). However, three (2.4%) HIV-exposed newborns have cleft palate compared with none in the unexposed group.
HIV infection was diagnosed in 87 (69%) mothers before the index pregnancy and 39 (31%) of the mothers were diagnosed HIV-infected during the index pregnancy at booking at the antenatal clinic. One hundred and nineteen (94.4%) mothers were on HAART for a duration ranging from 1 to 123 months with a mean duration of 27.14 AE 27.4 months, while seven (5.6%) mothers were not on HAART. Ninety-two (73.02%) mothers were on combination therapy with nevirapine, lamivudine and zidovudine, 21 (16.67%) were on combination of efavirenz, lamivudine and tenofovir, four (3.17%) were on combination of (atazanavir and ritonavir), tenofovir, zidovudine and lamivudine and two (1.59%) mothers were on other combination therapies that included lopinavir or abacavir. All the mothers in this study believed that their newborns can perceive sound. The comparison of HIV-exposed newborns with and without hearing loss is summarized in Table 2 .
Immunology
There is no statistically significant difference between the mean CD4 þ cell count of mothers of HIV-exposed newborns with hearing impairment and those without hearing impairment (P ¼ 0.13). The CD4 þ cell % of the HIV-exposed neonates ranged from 9.5 to 86.8% with a mean of 36.06 AE 14.85%, median of 33.70%. Ninety-seven (77%) HIV-exposed newborns had CD4 þ cell count percentage more than 25% and no correlation between the CD4 þ cell % of the newborns and their mothers' CD4 þ cell count was demonstrated (P ¼ 0.99, r ¼ 0.001).
Virology
None of the HIV-exposed newborns tested positive to HIV-1 by DNA PCR. The RNA viral load of 400 copies/ml or less was regarded as nondetectable. Sixty-two (49.2%) mothers had detectable RNA viral load with values ranging from 490 to 767 012 copies/ml with a median of 12 183. There is also no significant correlation between the RNA viral load of these HIVinfected mothers and duration on HAART (P ¼ 0.61; r ¼ 0.04).
Auditory brainstem response test
In the HIV-exposed and HIV-unexposed groups, there was more referred hearing in the left ear than the right ear ( Table 3 ). More HIV-exposed newborns had hearing loss (11.1%) than the HIV-unexposed newborn (6.6%), but the difference is not statistically significant (P ¼ 0.2214). About 6.4% of HIV-exposed newborns had hearing threshold more than 20 dBHL than 2.5% of HIV-unexposed newborns (P ¼ 0.1573) in the right ear with similar findings in the left ear ( Table 3 ). Five of the 14 HIVexposed newborns with SNHL were from mothers not on HAART. Six (42.9%) of the 14 HIV-exposed newborns with hearing loss had CD4 þ cell count percentage of 25 or less, while 14 (12.5%) of the remaining 112 HIV-exposed newborns had CD4% of 25 or less. There was a statistically significant difference in the right and left hearing thresholds of HIV-exposed newborns with CD4 þ cell count percentage of 25 or less compared with those with CD4 þ cell count percentage more than 25 (P ¼ 0.047; P ¼ 0.043, respectively). There was a strong association between the hearing threshold of the HIV-exposed newborns and CD4 þ cell counts of their mothers (r ¼ 0.62), but the relationship is not significant (P ¼ 0.059). There was a statistically significant relationship between hearing threshold of the HIV-exposed newborns and their mothers' viral load count (P ¼ 0.034).
There was a significant difference in the hearing of the 119 exposed newborns whose mothers were on HAART and those of the seven HIV-exposed newborns whose mothers were not (P ¼ 0.002; RR 0.13 95% CI 0.05-0.32). There was no significant difference in the 2226 AIDS 2014, Vol 28 No 15 Table 2 . Comparison of characteristics of HIV-exposed newborns with and without hearing loss.
Variables HIV-exposed newborns with hearing impairment HIV-exposed newborns without hearing impairment right and left hearing threshold of newborns exposed to nevirapine containing HAART in utero and those not exposed (P ¼ 0.303; P ¼ 0.263, respectively) and there was no difference in the right and left hearing threshold of newborns exposed to efavirenz containing HAART in utero and those not exposed (P ¼ 0.481; P ¼ 0.359, respectively).
Discussion
Neonatal detection of hearing loss and early intervention should be the standard of care in any country including Nigeria. Although the cause of hearing impairment is multifactorial in babies, the contribution of HIV/AIDS and exposure to antiretroviral medications in utero in HIV-exposed newborns was investigated in this study. This study reports the first determination and comparison of hearing status in HIV-exposed and HIV-unexposed newborns in sub-Saharan Africa where the burden of the disease is high.
The strength of this study is the thorough hearing evaluation performed on both the HIV-exposed and HIV-unexposed newborns. Additional strength of this study is the detailed information on HIV status of the mothers that was related with the hearing threshold of the HIV-exposed newborns. In this study, there was a trend towards more hearing loss in newborns exposed to maternal HIV in utero (11.1%) than newborns not exposed to maternal HIV (6.6%), but this did not reach significance (P ¼ 0.217). This confirms that hearing impairment in newborns starts soon after birth [24, 39] . A previous Brazilian hearing screening of infants born to HIV-seropositive mothers had reported a prevalence of 10% but found no association between HIV exposure during pregnancy and hearing loss [39] . The difference between the report of this present study and Manfredi et al. [39] may be due to the different electrophysiological tools used in the two studies. Although Manfredi et al.
[39] utilized otoacoustic emissions (OAEs) that measure cochlear functions and ABR measures the function of the auditory pathways for vestibulocochlear nerve, both instruments have however been successfully used in hearing screening of newborns. To prevent this disparity, the Joint Committee on Infant Hearing recommended a method of two-step automated OAE programme, completed by an ABR for the positive diagnosis of hearing impairment in all newborns at risk of hearing impairment [40] . Although using the two electrophysiologic tests of hearing tools for routine hearing screening is unaffordable in Nigeria, however, it has been reported that click ABR in babies referred for newborn hearing screening can predict the degree of hearing loss in them [41] , which was therefore used in the present study.
The high prevalence of SNHL found in this study supports the need for routine hearing screening for newborns. Although 6.4% HIV-exposed newborns had mild hearing loss as compared with 2.5% in the nonexposed group, this difference was not significant; however, the mild SNHL has been reported to interfere with language, education and psychosocial development of a child later in life [24, 33] . SNHL distorts auditory signals, as it leaves the cochlea to be processed at higher auditory centre, thereby incapacitating the development of communication ability of the affected individual.
The trend towards higher prevalence of SNHL among the HIV-exposed newborns than among the unexposed group may have association with the maternal HIV status. Vertical transmission of HIV from infected mothers to their foetuses or newborns has been documented [42, 43] . In Europe and United States of America, mother-tochild transmission has almost been eliminated, but it is still a problem in developing countries [44] . In the UK, HAART reduced the rate of HIV maternal-to-child transmission from 25.6% in 1993 [45] to 1.2% between 2000 and 2006. The rate was further reduced to 0.1% in mothers with undetectable viral load [46] . The
Hearing test in HIV-1 exposed newborns Fasunla et al. 2227 Table 3 . Comparison of Auditory Brainstem Response hearing screening outcome and hearing thresholds of the HIV-exposed and HIVunexposed newborns.
Variable
Hearing level (dB) HIV-exposed newborns HIV-DNA PCR tests performed on the participants at the neonatal period were negative for HIV-1 probably because the HAART used in pregnancy prevented transmission of HIV from the mothers to their babies. It is also possible that the hearing impairment in the five of the seven newborns of mothers who were not on ART may be associated with the in-utero effect of the virus; however, all the newborns were seronegative for HIV 1 at birth. Passive exposure to HIV-1 proteins in the absence of actual infection, or exposure to a pro-inflammatory environment during gestation, may have contributed to the observed effects on hearing threshold. HIV has been known to cause hearing impairment by attacking directly the cochlear and vestibulo-cochlear nerve [47] . The possibility of neurotropism of HIV in a developing brain causing peripheral and central hearing alteration has also been documented [47, 48] .
The limitation of the study is the inability to assess for toxoplasmosis and other viral infection such as CMV, toxoplasmosis and rubella known to cause hearing loss. None of the mothers had a positive VDRL. The ototoxic and vestibulotoxic side effects of some HAART medications have been reported [35, 36] , but the information on these side effects in HIV-exposed newborns is rare. Hearing loss has been reported in HIV-infected individual on stavudine, lamivudine and efavirenz [49] but not in those on zidovudine and didanosine [50] . However, there is no information on the hearing of HIV-exposed newborns who were exposed to any of these medications in utero. Inference from the present study demonstrated that there is lesser risk of hearing loss among newborns exposed to HAART in utero (P ¼ 0.002; RR 0.13); this trend can only be confirmed by a larger study on the role of HAART in the development of SNHL.
The CD4 þ cell count and CD4%, which measure the degree of immunosuppression in HIV-infected patients, is used in staging and monitoring disease, deciding when to commence therapy, defining the risk for mother-to-child transmission and determining treatment failure [51] [52] [53] . This study showed significant association between the CD4 þ cell % and hearing threshold of HIV-exposed newborns. Those with CD4 þ cell % of 25 or less had higher hearing threshold than those with more than 25%. Therefore, CD4 þ cell count percentage may be a useful predictor of hearing level in HIV-exposed newborns. There was a significant relationship between high maternal viral load as measured by HIV-RNA copies/ ml and higher hearing threshold levels in HIV-exposed babies. This suggests that HIV virus in mothers might have an effect on the sensory organ of hearing and/or the vestibulo-cochlear nerves of their newborns causing hearing loss, but this is difficult to postulate in the absence of HIV infection in the newborns. A larger population study would verify this observation and determine the role of the mothers' RNA viral load in predicting the hearing threshold of their babies.
One would expect that a short duration of HAART is associated with high RNA viral load seen in HIV-infected patients; however, there is no significant correlation between duration of antiretroviral treatment and RNA viral loads in this present study. Nonadherence to antiretroviral medications may be a possible factor for the high RNA viral load and mothers need to be adequately educated on the importance of regular intake of HAART medication on their health and babies.
Despite the observation in this study, other studies have shown that the hearing threshold of babies can change during infancy [54] . As auditory system of newborns might not have developed fully at birth [55] , a repeat of the hearing evaluation/assessment with electrophysiological hearing test later in infancy should confirm persistence, improvement or worsening of hearing loss, thereby necessitating timely treatment or rehabilitation with either hearing aid or cochlea implant in order to improve acquisition/development of normal speech and hearing. With the introduction of HAART, HIVexposed or -HIVinfected newborns now live longer and have a better quality of life, and therefore, the need for later evaluation of hearing is imperative.
Conclusion
Hearing loss is present in both the HIV-exposed and HIV-unexposed newborns and there is a trend of higher prevalence of SNHL in HIV-exposed newborns than in HIV-unexposed newborn. Routine hearing screening is therefore recommended to identify early newborns with hearing loss in all newborns including the HIV-exposed newborns. In addition, there is a reduced risk of developing hearing loss in newborns exposed to HAART in utero than those who were not. This finding needs further verification in a similar comparative study with a higher sample size of HIV-exposed newborns who are not exposed in utero to HAART. cooperative agreement with APIN (PS 001058). In addition, support was provided by the Fogarty International Center (NIH) R24TW008878 Medical Education Partnership in Nigeria. The contents are solely the responsibility of the authors and do not represent the official views of the funding institutions.
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